Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Protalix BioTherapeutics's Average Total Inventories for the quarter that ended in Jun. 2026 was $31.38 Mil. Protalix BioTherapeutics's Revenue for the
three
months ended in Jun. 2026 was $19.90 Mil.
Protalix BioTherapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 1.58.
Protalix BioTherapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2026
increased
from Mar. 2026 (0.83) to Mar. 2026 (1.58)
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Protalix BioTherapeutics's Days Inventory for the
three
months ended in Jun. 2026 was 368.94.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Protalix BioTherapeutics's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.25.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Protalix BioTherapeutics's Days Inventory for the
three
months ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics Inventory-to-Revenue Related Terms
Protalix BioTherapeutics Inventory-to-Revenue Historical Data
* Premium members only.
The historical data trend for Protalix BioTherapeutics's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PLX vs CUE, ORMP, ARMP: Inventory-to-Revenue Comparison
For the Biotechnology subindustry, Protalix BioTherapeutics's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protalix BioTherapeutics Inventory-to-Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Protalix BioTherapeutics's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Protalix BioTherapeutics's Inventory-to-Revenue for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics (PLX) has a Inventory-to-Revenue of 1.58 as of Jun. 2026. Inventory-to-Sales ratio is the total inventories divided by total sales. View historical data on Protalix BioTherapeutics and its competitors.
Is Protalix BioTherapeutics' Inventory-to-Revenue too high?
Protalix BioTherapeutics' current Inventory-to-Revenue is 1.58. Overall, Protalix BioTherapeutics has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' Inventory-to-Revenue compare to CUE and ORMP?
Protalix BioTherapeutics' Inventory-to-Revenue of 1.58 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory-to-Revenue for a Biotechnology company?
A good Inventory-to-Revenue depends on the Biotechnology industry context. However, Inventory-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory-to-Revenue mean?
A high Inventory-to-Revenue can signal that a stock is expensive relative to its fundamentals. Inventory-to-Sales ratio is the total inventories divided by total sales. View historical data on Protalix BioTherapeutics and its competitors. Protalix BioTherapeutics's current Inventory-to-Revenue is 1.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (PLX) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.20, compared to a current price of $2.68 — trading 21.8% above its estimated fair value. The current Inventory-to-Revenue is 1.58. Protalix BioTherapeutics' overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory-to-Revenue calculated?
Inventory-to-Revenue is calculated from a company's financial statements. For Protalix BioTherapeutics (PLX), the current Inventory-to-Revenue is 1.58 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protalix BioTherapeutics (PLX) Overvalued in 2026?
Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued.
The current stock price of $2.68 is trading 21.8% above its estimated GF Value™ of $2.20.
GuruFocus considers Protalix BioTherapeutics to be Modestly Overvalued.
Key valuation signals for PLX:
Inventory-to-Revenue: 1.58
GF Value™: $2.20 vs. price of $2.68 (21.8% above fair value)
No single metric tells the full story. See the PLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
60GF Score
Get the complete analysis for PLX
Inventory-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLX has been successfully added to your 
